1. New potential of Trimetazidine MB for coronary heart disease treatment in the real-world clinical practice: results of the Russian multi-centre randomised study PERSPECTIVE (Part II)
- Author
-
Bubnova, M. G., Aronov, D. M., Rafael Oganov, and Rudomanov, O. G.
- Subjects
medicine.medical_specialty ,stable angina ,Ejection fraction ,trimetazidine mb ,business.industry ,Standard treatment ,Trimetazidine ,medicine.disease ,Angina ,Heart failure ,Concomitant ,Internal medicine ,RC666-701 ,Ambulatory ,medicine ,Cardiology ,Diseases of the circulatory (Cardiovascular) system ,Decompensation ,coronary heart disease ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Aim. As a clinical part of the Russian multi-centre randomised study, to assess the clinical benefits and safety of adding Trimetazidine MB to the standard treatment scheme in patients with stable angina (SA), in order to optimise their ambulatory therapy and improve their compliance. Material and methods. The study included 981 patients with Functional Class (FC) II-III SA and various concomitant diseases and syndromes, such as chronic heart failure (CHF), Type 2 diabetes mellitus (DM-2), or chronic obstructive pulmonary disease (COPD) in smokers. All participants were divided into two groups: Group I (n=838) received standard therapy plus trimetazidine MB (70 mg/d, twice a day), while Group II (n=143) received standard therapy only. The treatment and follow-up phases lasted for 12 months. Results. In Group I, the weekly number of angina attacks decreased by 42 % from the baseline at one month (рррррррConclusion. The Russian “PERSPECTIVE” Study results demonstrated high clinical effectiveness and safety ofTrimetazidineMB therapy, combined with standard treatment, in SA patients with CHF, DM-2, and COPD. Therefore, metabolic therapy could be more widely used in the real-world clinical settings.
- Published
- 2011